Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 7/20 | 0.58 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16133830 | 1.00 | SCN4A (0.58) | SCN4ADPP4F2MAOAMAOB | |
| Hydrochloric Acid SCHEMBL8320866 | 0.98 | SCN4A (0.56) | SCN4ADPP4F2MAOAMAOB | |
| Hydrochloric Acid SCHEMBL14893289 | 0.98 | SCN4A (0.56) | SCN4ADPP4F2MAOAMAOB | |
| Hydrochloric Acid SCHEMBL11119740 | 0.85 | SLC6A4 (0.50) | SCN4AMAOAMAOB | |
| SCHEMBL19485922 | 0.80 | SCN4A (0.44) | SCN4ADPP4F2 | |
| SCHEMBL9299256 | 0.77 | MAOA (0.61) | SCN4ADPP4F2MAOAMAOB | |
| SCHEMBL21830962 | 0.76 | TSHR (0.46) | SCN4ADPP4F2TAAR1 | |
| SCHEMBL23192467 | 0.76 | SCN4A (0.49) | SCN4ATAAR1 | |
| SCHEMBL18012500 | 0.76 | MME (0.49) | SCN4A | |
| SCHEMBL8322134 | 0.75 | SCN4A (0.50) | SCN4ADPP4F2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054445-A1 | Amide Substituted Quinolines | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-1981882-A1 | AMIDE SUBSTITUTED QUINOLINES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | claimed |
| WO-2007086799-A1 | AMIDE SUBSTITUTED QUINOLINES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054445-A1 | Amide Substituted Quinolines | RECQL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0 | SCN4A 300/4885DPP4 2245/4885F2 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.